Results 1 to 10 of about 47,364 (165)
Management of ductal carcinoma in situ [PDF]
Ca-A Cancer Journal for Clinicians, 1995 The increased use of screening mammography in the past two decades has led to a marked increase in the number of patients diagnosed with ductal carcinoma in situ. Treatment has traditionally involved mastectomy, but this approach has come under increasing scrutiny, and the treatment of ductal carcinoma in situ has become one the most controversial ...
Mónica Morrow, S J Schnitt
exaly +3 more sources
Journal of Pathology of Nepal, 2023 Background: The clinical outcome of breast carcinoma varies in each individual due to its molecular heterogeneity. There is a rising interest in whether the associated ductal carcinoma in-situ in invasive ductal carcinoma of breast affects the prognosis ...
Dhivya Balaiya +2 more
doaj +1 more source
Immunohistochemical Expression of p63 in Benign and Malignant Breast Lesions [PDF]
Journal of Clinical and Diagnostic Research, 2021 Introduction: Breast carcinoma demands attention as it causes high morbidity and mortality. It is important to recognise benign lesions to distinguish them from in situ and invasive breast cancer and to assess a patient’s risk of developing breast ...
Abhishek Saini +6 more
doaj +1 more source
Ductal carcinoma in situ of the breast [PDF]
Indian Journal of Surgery, 2013 Ductal carcinoma in situ (DCIS) of the breast is a potentially invasive neoplasm. Risk factors include high estrogen states such as use of oral contraceptive (OC) pills, nulliparity, advanced age at first birth, and also family history and genetic mutations. The incidence of this usually clinically silent condition has risen in the past few decades due
Melvin J. Silverstein, Michael D. Lagios
openaire +3 more sources
대한영상의학회지, 2022 The incidence of ductal carcinoma in situ has increased with the rise in screening mammography; currently, ductal carcinoma in situ constitutes 20%–25% of all breast cancers, and up to half of them may become invasive.
Yeon Jung Kim, Hyun Kyung Jung, Woogyeong Kim
doaj +1 more source
Radiotherapy of Ductal Carcinoma In Situ [PDF]
Breast Care, 2015 Ductal carcinoma in situ (DCIS) is a heterogeneous disease in both its biology and clinical course. In the past, recurrence rates after breast-conserving surgery have been as high as 30% after 10 years. The introduction of mammography screening and advances in imaging have led to an increase in the detection of DCIS.
David, Krug, Rainer, Souchon
openaire +2 more sources
Galician Medical Journal, 2020 Breast carcinoma is a heterogeneous group of tumors with a wide spectrum of clinical presentations, lesion characterization and diagnostic evaluation.
Ankit Prabhakar +4 more
doaj +1 more source
Potential biomarkers of ductal carcinoma in situ progression
BMC Cancer, 2020 Background Ductal carcinoma in situ is a non-obligate precursor of invasive breast carcinoma and presents a potential risk of over or undertreatment. Finding molecular biomarkers of disease progression could allow for more adequate patient treatment.
Raquel Spinassé Dettogni +17 more
doaj +1 more source
Ductal Carcinoma In Situ of the Breast [PDF]
International Journal of Surgical Oncology, 2012 Ductal carcinoma in situ (DCIS) of the breast represents a complex, heterogeneous pathologic condition in which malignant epithelial cells are confined within the ducts of the breast without evidence of invasion. The increased use of screening mammography has led to a significant shift in the diagnosis of DCIS, accounting for approximately 27% of all ...
Lee, Richard J. +5 more
openaire +4 more sources
BMC Medical Imaging, 2020 Background The upgrade rate of biopsy-confirmed ductal carcinoma in situ (DCIS) to invasive carcinoma is up to 50% on final pathology. We investigated MRI and clinicopathologic predictors of the invasive components of DCIS diagnosed by preoperative ...
Ga Young Yoon +5 more
doaj +1 more source